scholarly journals Prosthetic thrombosis and coronary embolism during pregnancy: a delicate situation of antithrombotic therapy management

Author(s):  
Abdelilah Ben El Makki ◽  
Mohammed Malki ◽  
Hicham Faliouni ◽  
Mohammed Sabry

Mechanical heart valve thrombosis is not so rare in pregnant women because of the difficulties in managing anticoagulant treatment and the hypercoagulability state associated with pregnancy. Among the embolic complications of valve prosthetic thrombosis, the coronary embolism is rare, it requires an urgent pharmaco-invasive approach which must be adapted to this particular associated condition. We report the observation and the difficulties of managing antithrombotic therapy in a pregnant patient hospitalized for non-obstructive prosthetic valve thrombosis complicated by coronary embolism and resulting in ST elevation myocardial infarction.

2021 ◽  
pp. 1-3
Author(s):  
A. Shaheer Ahmed ◽  
Shivank Gupta

Abstract A 11-year-old with history of mitral valve replacement presented with low-grade fever, breathlessness and multiple episodes of haemoptysis for 2 days. Detailed echocardiographic evaluation revealed possible prosthetic valve thrombosis, which was confirmed by fluoroscopy. She was thrombolysed with low dose infusion of tenecteplase. Post thrombolysis her symptoms improved, valve mobility was restored, and haemoptysis subsided. Left sided prosthetic valve thrombosis presenting predominantly with haemoptysis is very rare.


Author(s):  
Freek W. A. Verheugt

Fibrinolytic agents are able to reopen blood vessels that are occluded by a fresh thrombus. Urokinase, streptokinase, and streptokinase derivatives were the first effective agents. Recombinant plasminogen activators became available and they are specific for thrombus-bound fibrin. Significant bleeding is the major side effect of fibrinolysis, a major hurdle for its use. The current era of mechanical reperfusion has made fibrinolytic therapy a niche treatment for acute arterial thrombosis such as ST elevation myocardial infarction and stroke. Only for pulmonary embolism with haemodynamic consequences and mechanical heart valve thrombosis may lytic therapy have a place in selected patients.


2015 ◽  
Vol 8 (5) ◽  
pp. 756-757 ◽  
Author(s):  
Macit Kalçık ◽  
Mahmut Yesin ◽  
Mustafa Ozan Gürsoy ◽  
Süleyman Karakoyun ◽  
Mehmet Özkan

ESC CardioMed ◽  
2018 ◽  
pp. 200-203
Author(s):  
Freek W. A. Verheugt

Fibrinolytic agents are able to reopen blood vessels that are occluded by a fresh thrombus. Urokinase, streptokinase, and streptokinase derivatives were the first effective agents. Recombinant plasminogen activators became available and they are specific for thrombus-bound fibrin. Significant bleeding is the major side effect of fibrinolysis, a major hurdle for its use. The current era of mechanical reperfusion has made fibrinolytic therapy a niche treatment for acute arterial thrombosis such as ST elevation myocardial infarction and stroke. Only for pulmonary embolism with haemodynamic consequences and mechanical heart valve thrombosis may lytic therapy have a place in selected patients.


2016 ◽  
Vol 25 (4) ◽  
pp. 414-415 ◽  
Author(s):  
Macit Kalçık ◽  
Mahmut Yesin ◽  
Mustafa Ozan Gürsoy ◽  
Süleyman Karakoyun ◽  
Mehmet Özkan

Sign in / Sign up

Export Citation Format

Share Document